Maricic Michael
Catalina Pointe Clinical Research, Inc., Tucson, Arizona 85704, USA.
Drugs Today (Barc). 2007 Dec;43(12):879-85. doi: 10.1358/dot.2007.43.12.1141564.
Paget's disease of bone is a common skeletal disorder that often results in significant pain and disability. A number of bisphosphonates are currently available for treatment, however normalization of biochemical markers of bone turnover (the goal of treatment of Paget's disease) is rarely accomplished with currently available medications due to difficulty with administration, poor long-term adherence and possibly resistance to individual bisphosphonates. This review will focus on zoledronic acid, a potent intravenous bisphosphonate that appears to result in a higher percentage of patients with long-term normalization of markers of bone turnover than previously available drugs, thereby improving quality of life in patients with Paget's disease of bone.
骨佩吉特病是一种常见的骨骼疾病，常导致严重疼痛和残疾。目前有多种双膦酸盐可用于治疗，然而，由于给药困难、长期依从性差以及可能对个别双膦酸盐产生耐药性，目前可用的药物很少能使骨转换生化标志物（骨佩吉特病治疗的目标）恢复正常。本综述将聚焦于唑来膦酸，一种强效静脉用双膦酸盐，与先前可用的药物相比，它似乎能使更高比例的患者骨转换标志物长期恢复正常，从而改善骨佩吉特病患者的生活质量。
